Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: Results of a multicenter, placebo-controlled, randomized trial Academic Article uri icon

Overview

MeSH Major

  • Benzamidines
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex

abstract

  • Xemilofiban inhibited platelet aggregation and was well tolerated during 28 days of long-term oral therapy. The observed trend in reduction of cardiovascular events in follow-up awaits confirmation in the larger-scale phase III study (EXCITE trial) currently in progress.

publication date

  • September 29, 1998

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 9751674

Additional Document Info

start page

  • 1268

end page

  • 78

volume

  • 98

number

  • 13